Page 10 - Guide de pratique de l’Association des urologues du Canada : Cancer de la vessie avec envahissement musculaire

Kulkarni et al.

40. Larcher A, Sun M, Schiffmann J et al. Differential effect on survival of pelvic lymph node dissection at 56. Yafi FA, Kassouf W. Management of patients with advanced bladder cancer following major response
radical cystectomy for muscle-invasive bladder cancer. Eur J Surg Oncol 2015;41:353-60. https://doi. to systemic chemotherapy. Expert Rev Anticancer Ther 2009;9:1757-64. https://doi.org/10.1586/
org/10.1016/j.ejso.2014.10.061 era.09.148
41. Abdi H, Pourmalek F, Gleave ME et al. Balancing risk and benefi t of extended pelvic lymph node dissec-Balancing risk and benefit of extended pelvic lymph node dissec- 57. Abe T, Matsumoto R, Shinohara N. Role of surgical consolidation in metastatic urothelial carcinoma. Curr
tion in patients undergoing radical cystectomy. World J Urol 2016;34:41-8. https://doi.org/10.1007/ Opin Urol 2016;26:573-80. https://doi.org/10.1097/MOU.0000000000000329
s00345-015-1734-x 58. Basch E, Deal AM, Dueck AC et al. Overall survival results of a trial assessing patient-reported
42. Ho PL, Willis DL, Patil J et al. Outcome of patients with clinically node-positive bladder cancer undergoing outcomes for symptom monitoring during routine cancer treatment. JAMA 2017;318:197-8.
consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. Urol https://doi.org/10.1001/jama.2017.7156
Oncol 2016;34:59.e1-8. https://doi.org/10.1016/j.urolonc.2015.08.012 59. Garg T, Connors JN, Ladd IG et al. Defining priorities to improve patient experience in non-muscle invasive
43. Wright JL, Lin DW, Porter MP. The association between extent of lymphadenectomy and survival among bladder cancer. Bladder Cancer 2018;4:121-8. https://doi.org/10.3233/BLC-170138
patients with lymph node metastases undergoing radical cystectomy. Cancer 2008;112:2401-8. 60. Smith AB, Jaeger B, Pinheiro LC et al. Impact of bladder cancer on health-related quality of life. BJU Int
https://doi.org/10.1002/cncr.23474 2018;121:549-57. https://doi.org/10.1111/bju.14047
44. Wiesner C, Salzer A, Thomas C et al. Cancer-specific survival after radical cystectomy and standardized 61. Gilbert SM, Lai J, Saigal CS et al. Urologic Diseases in America Project. Downstream complications fol-Urologic Diseases in America Project. Downstream complications fol-
extended lymphadenectomy for node-positive bladder cancer: prediction by lymph node positivity and lowing urinary diversion. Urology 2013;190:916-22. https://doi.org/10.1016/j.juro.2013.03.026
density. BJU Int 2009;104:331-5. https://doi.org/10.1111/j.1464-410X.2009.08403.x 62. Nazmy M, Yuh B, Kawachi M et al. Early and late complications of robot-assisted radical cystectomy: A
45. Gschwend JE, Heck MM, Lehmann J et al. Extended vs. limited lymph node dissection in bladder cancer standardized analysis by urinary diversion type. J Urol 2014;191:681-7. https://doi.org/10.1016/j.
patients undergoing radical cystectomy: Survival results from a prospective, randomized trial. Eur Urol juro.2013.10.022
2019;75:604-11. https://doi.org/10.1016/j.eururo.2018.09.047 63. Shah SH, Movassaghi K, Skinner D et al. Ureteroenteric strictures after open radical cystectomy
46. Kulkarni GS, Urbach DR, Austin PC et al. Longer wait times increase overall mortality in patients with and urinary diversion: The University of Southern California experience. Urology 2015;86:87-91.
bladder cancer. J Urol 2009;182:1318-24. https://doi.org/10.1016/j.juro.2009.06.041 https://doi.org/10.1016/j.urology.2015.03.014
47. Tyson MD, Chang SS. Enhanced recovery pathways vs. standard care after cystectomy: A meta-analysis 64. Huddart RA, Birtle A, Maynard L et al. Clinical and patient-reported outcomes of SPARE — a randomized
of the effect on perioperative outcomes. Eur Urol 2016;70:995-1003. https://doi.org/10.1016/j. feasibility study of selective bladder preservation vs. radical cystectomy. BJU Int 2017;120:639-50.
eururo.2016.05.031 https://doi.org/10.1111/bju.13900
48. Melnyk M, Casey RG, Black P et al. Enhanced recovery after surgery (ERAS) protocols: Time to change 65. Feuerstein MA, Goenka A. Quality of life outcomes for bladder cancer patients undergoing bladder preserva-
practice? Can Urol Assoc J 2011;5:342-8. https://doi.org/10.5489/cuaj.11002 tion with radiotherapy. Curr Urol Rep 2015;16:75. https://doi.org/10.1007/s11934-015-0547-1
49. Enhanced Recovery after Abdominal Surgery (ERAS) protocols in the urologic setting: Focus on radical 66. Boer H, Proost JH, Nuver J et al. Long-term exposure to circulating platinum is associated with late effects
cystectomy. Canadian Urological Association, 2016. À l’adresse : https://www.cua.org/en/cpdcme. of treatment in testicular cancer survivors. Ann Oncol 2015;26:2305-10. https://doi.org/10.1093/
er
Consulté le 1 février 2018. annonc/mdv369
50. Muppa P, Gupta S, Frank I et al. Prognostic significance of lymphatic, vascular and perineural invasion 67. Stewart-Merrill SB, Boorjian SA, Thompson RH et al. Evaluation of current surveillance guidelines fol-
for bladder cancer patients treated by radical cystectomy. Pathology 2017;49:259-66. https://doi. lowing radical cystectomy and proposal of a novel risk-based approach. Urol Oncol 2015;33:339.e1-8.
org/10.1016/j.pathol.2016.12.347 https://doi.org/10.1016/j.urolonc.2015.04.017
51. Gore JL, Litwin MS, Lai J et al. Urologic Diseases in America Project. Use of radical cystectomy for patients 68. Yafi FA, Aprikian AG, Fradet Y et al. Surveillance guidelines based on recurrence patterns after radical
with invasive bladder cancer. J Natl Cancer Inst 2010;102:802-11. https://doi.org/10.1093/jnci/ cystectomy for bladder cancer: The Canadian Bladder Cancer Network experience. BJU Int 2012;110:1317-
djq121 23. https://doi.org/10.1111/j.1464-410X.2012.11133.x
52. Caffo O, Veccia A, Fellin G et al. Trimodality treatment in the conservative management of infiltrat- 69. Haun MW, Estel S, Rücker G et al. Early palliative care for adults with advanced cancer. Cochrane Database
ing bladder cancer: A critical review of the literature. Crit Rev Oncol Hematol 2013;86:176-90. Syst Rev 2017; 6:CD011129. https://doi.org/10.1002/14651858.CD011129.pub2
https://doi.org/10.1016/j.critrevonc.2012.09.011 70. Yafi FA, North S, Kassouf W. First- and second-line therapy for metastatic urothelial carcinoma of the
53. James ND, Hussain SA, Hall E et al. BC2001 Investigators. Radiotherapy with or without chemotherapy bladder. Curr Oncol 2011;18:e25-34. https://doi.org/10.3747/co.v18i1.695
in muscle-invasive bladder cancer. N Engl J Med 2012;366:1477-88. https://doi.org/10.1056/ 71. Vishnu P, Mathew J, Tan WW. Current therapeutic strategies for invasive and metastatic bladder cancer.
NEJMoa1106106 Onco Targets Ther 2011;4:97-113. https://doi.org/10.2147/OTT.S22875
54. Coen JJ, Zhang P, Saylor PJ et al. Bladder preservation with twice-a-day radiation plus fluorouracil/cisplatin
or once-daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG/RTOG 0712 — a ran- Correspondance: D Girish S. Kulkarni, Division d’urologie, Départements de chirurgie et d’oncologie
r

domized phase 2 trial. J Clin Oncol 2018;15:JCO1800537. https://doi.org/10.1200/JCO.18.00537 chirurgicale, Princess Margaret Cancer Center, University Health Network, Université de Toronto,
55. Ghadjar P, Burkhard FC, Gautschi O et al. Induction chemotherapy for unresectable urothelial carcinoma Toronto (Ont.), Canada; Girish.Kulkarni@uhn.ca
of the bladder. BJU Int 2011;107:894-7. https://doi.org/10.1111/j.1464-410X.2010.09574.x

R56 CUAJ • August 2019 • Volume 13, numéro 8